SSSW(SH:688399) 智通财经网·2026-02-27 15:51Core Viewpoint - The company reported a total operating revenue of 340 million yuan for the fiscal year 2025, reflecting a year-on-year decline of 2.64% and a net loss attributable to shareholders of 39.71 million yuan [1] Group 1: Financial Performance - The company achieved total operating revenue of 340 million yuan, which is a decrease of 2.64% compared to the previous year [1] - The net loss attributable to the parent company's shareholders was 39.71 million yuan [1] - The net loss after deducting non-recurring gains and losses was 104 million yuan [1] Group 2: Business Environment - The company's main business showed stable development during the reporting period [1] - The decline in revenue from self-produced diagnostic reagent products was influenced by intensified industry competition and ongoing medical procurement [1] - The value-added tax rate for self-produced diagnostic reagents was adjusted to 13%, contributing to the revenue decline [1]